Allena, which is developing treatments for kidney diseases, took its overall funding to $93m in a round featuring returning investor Pharmstandard.
US-based biopharmaceutical company Allena Pharmaceuticals raised $53m in a series C round on Wednesday featuring Pharmstandard International, the holding company for Russia-based pharmaceutical firm OJSC Pharmstandard.
Hedge fund sponsor Partner Fund Management led the round, which also featured financial services conglomerate Fidelity Management and Research, Wellington Management, Frazier Healthcare and HBM BioCapital.
Founded in 2011, Allena is working on treatments for metabolic and orphan diseases. The company is currently conducting two phase 2 clinical trials for its lead program Alln-177,…
